Cerebral and ocular toxicity induced by desferrioxamine.

No abstract is available for this paper.

• Publication year

  1985

• Venue

  The Quarterly journal of medicine

• Publication date

  1985-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/OXFORDJOURNALS.QJMED.A067880PMID 4095247
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Age pigments: role of iron and copper salts in the formation of fluorescent lipid complexes.

  1984cited by this paper
• Visual loss in patient on high-dose subcutaneous desferrioxamine.

  1984cited by this paper
• Oxygen toxicity, oxygen radicals, transition metals and disease.

  1984cited by this paper
• Copper-phenanthroline-induced site-specific oxygen-radical damage to DNA. Detection of loosely bound trace copper in biological fluids.

  1984cited by this paper
• Chemistry and metabolism of lipids in the vertebrate retina.

  1983cited by this paper
• Ocular toxicity of high-dose intravenous desferrioxamine.

  1983cited by this paper
• On the Nature of the Interaction Between Serotonin and Serotonin Binding Protein: Effect of Nucleotides, Ions, and Sulfhydryl Reagents

  1982cited by this paper
• Effects of Iron Deficiency on Serotonin Uptake In Vitro by Rat Brain Synaptic Vesicles

  1982cited by this paper
• Production of superoxide, hydrogen peroxide and hydroxyl radicals by phagocytic cells: a cause of chronic inflammatory disease?

  1982cited by this paper
• Free-radical oxidation (peroxidation) products in serum and synovial fluid in rheumatoid arthritis.

  1981cited by this paper
• Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts. Detection of 'free' iron in biological systems by using bleomycin-dependent degradation of DNA.

  1981cited by this paper
• The importance of iron in rheumatoid disease.

  1981cited by this paper
• Tryptophan hydroxylase. The role of oxygen, iron, and sulfhydryl groups as determinants of stability and catalytic activity.

  1980cited by this paper
• Properties of ionophores with broad range cation selectivity.

  1973cited by this paper
• METAL CHELATES IN THE STORAGE AND TRANSPORT OF NEUROTRANSMITTERS: INTERACTIONS OF METAL IONS WITH BIOGENIC AMINES 1

  1971cited by this paper
• Spectrophotometric determination of serum iron at the submicrogram level with a new reagent (ferrozine).

  1971cited by this paper

• Deferoxamine-induced neurotoxicity: Role of chaperone-mediated autophagy dysfunction in neuronal apoptosis in the hippocampus.

  2024cites this paper
• Disproportionality analysis of data from VigiBase and other global product safety databases on toxicity of iron chelating agents

  2024cites this paper
• Heavy Metal Antagonists and Miscellaneous Drugs

  2021cites this paper
• HPO iron chelator, CP655, causes the G1/S phase cell cycle block via p21 upregulation

  2020cites this paper
• Drug Induced Maculopathies

  2020cites this paper
• Effects of iron chelating agent on Schistosoma mansoni infected murine model.

  2019cites this paper
• Oral nucleic acid therapy using multicompartmental delivery systems.

  2018cites this paper
• Multimodal Imaging in Drug-Related Retinal Toxicity

  2018cites this paper
• Neuroprotection of brain-permeable iron chelator VK-28 against intracerebral hemorrhage in mice

  2017cites this paper
• Retinal abnormalities in β-thalassemia major.

  2016cites this paper
• Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature

  2015cites this paper
• Neuroprotective effects of three different sizes nanochelating based nano complexes in MPP(+) induced neurotoxicity

  2015cites this paper
• Toxicity of Ophthalmic Solutions, Benzalkonium Chloride and UV Radiation on Human Corneal Epithelial Cells in vitro

  2015cites this paper
• Deferoxamine retinopathy: spectral domain-optical coherence tomography findings

  2014cites this paper
• The desferrioxamine-prochlorperazine coma—clue to the role of dopamine-iron recycling in the synthesis of hydrogen peroxide in the brain

  2014cites this paper
• Nanotherapeutics for Alzheimer’s disease (AD): Past, present and future

  2012cites this paper
• Clinical Use of Iron Chelators

  2012cites this paper
• Elevated labile Cu is associated with oxidative pathology in Alzheimer disease.

  2012cites this paper
• nonoverloaded mice 3-hydroxypyridin-4- one iron chelators in overloaded and Comparison of the subacute toxicity and efficacy of

  2011cites this paper
• Plasmodium falciparum parasitemia (see comments) Iron chelation with desferrioxamine B in adults with asymptomatic

  2011cites this paper
• chelators in mice (see comments) Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron

  2011cites this paper
• Does the O'Brien cycle occur in vivo as a key component in H(2)O(2) production and redox signalling?

  2011cites this paper
• Nanoparticle and iron chelators as a potential novel Alzheimer therapy.

  2010cites this paper
• Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.

  2010cites this paper
• Chapter 5 - Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease.

  2009cites this paper
• Nanoparticles in cellular drug delivery.

  2009cites this paper
• Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease.

  2009cites this paper
• Neuroprotective strategies in parkinson’s disease: protection against progressive nigral damage induced by free radicals

  2009cites this paper
• Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease.

  2009cites this paper
• Retinal Toxicity of Systemic Medications

  2008cites this paper
• Possible Mechanisms Underlying Potentiating Effects of Iron Chelators in Hematopoietic Response to Erythropoietin

  2008cites this paper
• Unifying Mechanism for Eye Toxicity: Electron Transfer, Reactive Oxygen Species, Antioxidant Benefits, Cell Signaling and Cell Membranes

  2008cites this paper
• DEFEROXAMINE-RELATED OCULAR TOXICITY: Incidence and Outcome in a Pediatric Population

  2008cites this paper
• Nanoparticles: a step forward for iron chelation in the brain

  2007cites this paper
• Iron chelation, quo vadis?

  2007cites this paper
• Iron chelators as therapeutic iron depletion agents

  2006cites this paper
• Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance.

  2006cites this paper
• OCULAR SIDE EFFECTS OF DESFERAL IN PATIENTS WITH β THALASSEMIA

  2006cites this paper
• Designing drug-delivery systems for the nervous system using nanotechnology: opportunities and challenges

  2006cites this paper
• Antioxidant effect of bisphosphonates and simvastatin on chondrocyte lipid peroxidation.

  2006cites this paper
• The anti-inflammatory effects ofd-myo-inositol-1.2.6-trisphosphate (PP56) on animal models of inflammation

  2005cites this paper
• A scientific rationale for protective therapy in Parkinson's disease

  2005cites this paper
• Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis

  2005cites this paper
• Comment Is Iron Sufficiency a Risk Factor in Ischemic Heart Disease ?

  2005cites this paper
• Nanoparticle and other metal chelation therapeutics in Alzheimer disease.

  2005cites this paper
• Subungual splinter haemorrhages : A new sign of the antiphospholipid coagulopathy ?

  2004cites this paper
• Anaemia in rheumatoid arthritis: pathogenesis, diagnosis and treatment

  2004cites this paper
• Schießscheiben-Makula durch Deferoxamin-Behandlung

  2004cites this paper
• Incidence of febrile seizures in thalassemic patients.

  2004cites this paper
• [Bull's-Eye Maculopathy with Deferoxamine Treatment].

  2004cites this paper
• Benefits and Risks of Deferiprone in Iron Overload in Thalassaemia and Other Conditions

  2003cites this paper
• Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia.

  2002cites this paper
• Results of long term iron chelation treatment with deferoxamine.

  2002cites this paper
• Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria.

  2002cites this paper
• The expanded clinical spectrum of deferoxamine retinopathy.

  2002cites this paper
• Desferrioxamine decreases NAD redox potential of intact red blood cells: evidence for desferrioxamine as an inducer of oxidant stress in red blood cells

  2002cites this paper
• Noninvasive recording and response characteristics of the rat dc-electroretinogram

  2002cites this paper
• Practical management of iron overload

  2001cites this paper
• Secondary iron overload.

  2001cites this paper
• The effects of local administration of lactoferrin on inflammation in murine autoimmune and infectious arthritis.

  2000cites this paper
• Desferrioxamine (DFO) conjugated with starch decreases NAD redox potential of intact red blood cells (RBC): Evidence for DFO as an extracellular inducer of oxidant stress in RBC

  2000cites this paper
• Fluorescein angiographic changes in acute toxic retinopathy associated with polypharmacy.

  2000cites this paper
• Redox Aspects of Signaling by Catecholamines and Their Metabolites

  2000cites this paper
• CSF copper concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease

  2000cites this paper
• Prooxidant activity of ferrioxamine in isolated rat hepatocytes and linoleic acid micelles.

  1999cites this paper
• Inhibition of skeletal sarcoplasmic reticulum Ca2+-ATPase activity by deferoxamine nitroxide free radical.

  1999cites this paper
• The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: Functional interrelationships in health and disease: A review — discussion

  1999cites this paper
• Iron, lactoferrin and iron regulatory protein activity in the synovium; relative importance of iron loading and the inflammatory response

  1998cites this paper
• [An experimental study of ototoxicity induced by deferoxamine mesilate].

  1998cites this paper
• Understanding cell death in parkinson's disease

  1998cites this paper
• Neurophysiologic evaluation of long-term desferrioxamine therapy in beta-thalassemia patients.

  1998cites this paper
• Erythropoietin and iron.

  1997cites this paper
• A Risk-Benefit Assessment of Iron-Chelation Therapy

  1997cites this paper
• Anti-oxidant therapy: does it have a role in the treatment of human disease?

  1997cites this paper
• Short-term oral 3-hydroxypyridin-4-one dosing increases aluminum excretion and partially reverses aluminum-induced toxicity in the rabbit independent of chelator lipophilicity.

  1997influential citation
• Clinical applications of commonly used contemporary antidotes. A US perspective.

  1997cites this paper
• Prevention of postasphyxia electroretinal dysfunction with a pyridoxal hydrazone.

  1997cites this paper
• Clinical Applications of Commonly Used Contemporary Antidotes

  1997cites this paper
• Liver iron depletion and toxicity of the iron chelator Deferiprone (L, CP20) in the guinea pig

  1997cites this paper
• The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders.

  1997cites this paper
• Clinical studies of iron chelators in malaria.

  1996cites this paper
• Characterization of drugs as antioxidant prophylactics.

  1996cites this paper
• Clinical Studies of Iron-Chelating Treatment in Malaria

  1996cites this paper
• Drug-Induced Ocular Side Effects

  1996cites this paper
• The 3-hydroxypyridin-4-ones more effectively chelate aluminum in a rabbit model of aluminum intoxication than does desferrioxamine.

  1996cites this paper
• Molecular Biology of Hematopoiesis 5

  1996cites this paper
• Adverse effects of aluminium-chelating compounds for clinical use.

  1996cites this paper
• Risks of parenteral deferoxamine for acute iron poisoning.

  1996cites this paper
• Oxidative stress, brain iron and neurodegeneration. Basic principles

  1996cites this paper
• Neuropsychological Toxicology

  1995cites this paper
• Ischaemia-reperfusion injury--a small animal perspective.

  1995cites this paper
• Myasthenia gravis following iron chelation therapy with intravenous desferrioxamine

  1995cites this paper
• Advances in the pathophysiology and treatment of thalassemia.

  1995cites this paper
• Oxidative stress in neurobiology: An important role for iron

  1995cites this paper
• Is there a rationale for iron supplementation in the treatment of akathisia? A review of the evidence.

  1995cites this paper
• The ototoxicity of deferoxamine mesylate.

  1995cites this paper
• Reactive Oxygen: Recent Therapeutic Intervention Strategies

  1995cites this paper
• Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.

  1995cites this paper
• Deferoxamine Mesylate-Associated Sensorineural Hearing Loss

  1995cites this paper
• Bleomycin and metal interactions

  1994cites this paper